Management of Adverse Events in Patients With HR+/HER2- Metastatic Breast Cancer
Virginia Kaklamani, MD, DSc, explains that managing adverse events like fatigue, GI toxicity, and musculoskeletal pain in patients with HR+/HER2- metastatic breast cancer using approaches such as exercise, anti-nausea medication, acupuncture, and supplements is key to meeting the dual treatment goals of prolonging life and maintaining quality of life.
EP: 1.Patient Case: A 56-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer and Visceral Metastases
EP: 2.Unmet Needs in the Treatment of Patients With Metastatic Breast Cancer With Visceral Metastases
EP: 3.The Impact of Biomarkers in Clinical Decision-Making and Emergent Agents in HR+/HER2- Metastatic Breast Cancer
EP: 4.Review of EMERALD Subgroup Analysis Data From SABCS 2023
EP: 5.Selecting a Second-Line Therapy for a Patient With HR+/HER2- mBC After Progression on ET + CDK4/6i Therapy
EP: 6.Management Approaches for HR+/HER2- mBC Based on Metastasis Location and Disease Burden
EP: 7.Management of Adverse Events in Patients With HR+/HER2- Metastatic Breast Cancer
EP: 8.Future Directions in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
